Adverum Biotechnologies Inc (ADVM)
7.525
+0.12
(+1.55%)
USD |
NASDAQ |
Nov 04, 16:00
7.53
0.00 (0.00%)
After-Hours: 20:00
Adverum Biotechnologies Cash from Investing (Quarterly): -2.327M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -2.327M |
| March 31, 2024 | -22.03M |
| December 31, 2023 | -9.878M |
| September 30, 2023 | 18.20M |
| June 30, 2023 | 67.02M |
| March 31, 2023 | 21.53M |
| December 31, 2022 | 2.234M |
| September 30, 2022 | 24.37M |
| June 30, 2022 | 30.74M |
| March 31, 2022 | 84.38M |
| December 31, 2021 | 23.88M |
| September 30, 2021 | 10.47M |
| June 30, 2021 | 37.78M |
| March 31, 2021 | 6.579M |
| December 31, 2020 | 11.58M |
| September 30, 2020 | -132.37M |
| June 30, 2020 | -88.63M |
| March 31, 2020 | -70.74M |
| December 31, 2019 | -19.21M |
| September 30, 2019 | -15.02M |
| June 30, 2019 | -36.59M |
| March 31, 2019 | 2.745M |
| December 31, 2018 | 8.027M |
| Date | Value |
|---|---|
| September 30, 2018 | 21.14M |
| June 30, 2018 | 14.90M |
| March 31, 2018 | 25.38M |
| December 31, 2017 | 34.69M |
| September 30, 2017 | 2.625M |
| June 30, 2017 | -20.67M |
| March 31, 2017 | -138.85M |
| December 31, 2016 | -0.924M |
| September 30, 2016 | -0.362M |
| June 30, 2016 | 2.445M |
| March 31, 2016 | 37.62M |
| December 31, 2015 | 30.06M |
| September 30, 2015 | 9.323M |
| June 30, 2015 | 7.827M |
| March 31, 2015 | -88.78M |
| December 31, 2014 | -0.364M |
| September 30, 2014 | -0.105M |
| June 30, 2014 | -0.427M |
| March 31, 2014 | -0.047M |
| December 31, 2013 | -0.009M |
| September 30, 2013 | -0.001M |
| June 30, 2013 | -0.003M |
| March 31, 2013 | -0.078M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-132.37M
Minimum
Sep 2020
84.38M
Maximum
Mar 2022
-0.3383M
Average
10.47M
Median
Sep 2021
Cash from Investing (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | -160.40M |
| Cassava Sciences Inc | -0.029M |
| Regenxbio Inc | -0.268M |
| Editas Medicine Inc | 51.95M |
| Apellis Pharmaceuticals Inc | -0.09M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.84M |
| Cash from Financing (Quarterly) | -0.116M |
| Free Cash Flow | -89.12M |
| Free Cash Flow Per Share (Quarterly) | -0.9524 |
| Free Cash Flow Yield | -82.31% |